tradingkey.logo

BRIEF-Novo Nordisk Says It Is Meeting Or Exceeding Expected U.S. Demand For Semaglutide Medicines

ReutersFeb 21, 2025 3:17 PM

- Novo Nordisk A/S NOVOb.CO:

  • FDA DECLARES WEGOVY® AND OZEMPIC® SHORTAGE IS OVER AND THAT NOVO NORDISK IS FULLY MEETING OR EXCEEDING NATIONWIDE DEMAND FOR ALL DOSES

  • NOVO NORDISK: ALL DOSES OF FDA-APPROVED SEMAGLUTIDE MEDICINES ARE BEING CONTINUOUSLY SHIPPED, MEETING OR EXCEEDING EXPECTED U.S. DEMAND

  • NOVO NORDISK - FDA'S DECISION MEANS THAT MAKING OR SELLING KNOCKOFF COMPOUNDED DRUG THAT IS ESSENTIALLY A COPY OF OZEMPIC OR WEGOVY IS ILLEGAL

Source text: ID:nPn3ClKD7a

Further company coverage: [NOVOb.CO]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI